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Aprotinin is a protease inhibitor isolated from bo-
vine lungs and othcr lissues. Its biochcmical struc!Urc, a 
single-chain polypeptide of 6.5 12 kD , and biophysical 
properties are weH defined. I The activity of commcrcial 
preparations of apralini n is usually describcd in kallikrein 
inac ti valor unils (KIU) , 0. 1 million KIU being equivalent 
102. 15 j-Lmol of apralinin per liter. Sy inhibiting tryps in , 
plasmin , plasma kallikrein , and ti ssue kallikreins in addi -
tion 10 othcr serine proteases, aprol in in can affeel the 
fibrinolytic and coagu lation, complement , and olher bio-
logie systems. I 
Apralinin has Ileen shown 10 reduce blood product 
requiremenls significantly in cardiac surgery in a well-
designed randomized double-blind ITial. 2 The ro le of 
aprolinin in cardiac surgery has bcen confimled in sev-
eral clinical sludies,3.4 and this subslance is now uscd 
roulinely in many cardiac units in Europe. 
Several pathological conditions can be encounlered 
in liver lransplanl recipienls. especially (hose individuals 
afflicted with advanced cirrhoses of the li ver. wh ich 
make them particularly vulnerable to increased blood 
loss. These risk faclors include preoperatively dccreased 
synlhcsis of cloning faclors, Ihrombocylopenia second-
ary 10 hypcrsplcnism, occasionally low-grade fibrinoly-
sis associated with endotoxemia. and the surgical risks 
attributable 10 portal hypertension with extremely vulner-
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able venous collaterals and, somelimes, multiple adhe-
sions because of prcvious hepatobiliary or portal decom-
pressive surgery. In addition, hyperfibrinolysis is 
espccially pronounced in the late anhepatic phase and 
immed iately after revascularization of the cold-slored 
graft , as has bcen shown by a number of studies . S--7 
Thc Pittsburgh liver transplant group has shown that 
the degree of blood usage during ortholOpic li ver trans-
plantation (OLT) correlates significantl y with postopera-
tive mortality during the first half year after the proce-
dure .8 Excessive blood loss may lead to prolonged 
intubation and ventilation , impainnent ofrenal function , 
and an incrcased risk of infcc tion. Preventing excessive 
blood loss during li ver transplanlation may thus contrib-
ute to improvements of the overall results. Because 
hypcrfibrinolysis plays a significant role in liver trans-
plantation , and bccause aprotinin acts as an antifibrin-
olytic agent, the potential role of aprotinin in liver trans-
plantation has been in vestigatcd . 
CLiNICAL STUDIES OF APROTININ IN 
LlVER TRANSPLANTATION 
In the initial rcport of a potentially beneficial effect 
of aprotinin in li ver transplantation ,9 the agent was givcn 
only as a bolus of 0.5 million KIU during induction of 
anesthesia , immediately prior to the anhepatic phase, and 
immediately prior to reperfus ion. This low-dose bolus 
regimen was givcn instead of the continuous infusion 
promoted by the cardiac surgery study of Royston el al 2 
because offear of a higher ri sk of subseq uenl Ihromboses 
of vascular anastomoses in the setting of liver transplan-
tation without intraoperati ve anticoagulation. In the ini-
tial study of 10 consecutive primary allografts and 10 
previous historie co ntrols, a significant reduction of 
blood product requiremenls following reperfusion of Ihe 
graft and a significanll y shorter operating lime from Ihe 
lime of reperfusion unlil skin closure were noted.9 Addi -
lionalJ y. the operative fi eld was often observed to be 
"bone dry" at the end of Ihe procedure , unlike the previ-
ously common diffuse oozing from previously dry sur-
faces. Such an unusually dry surgical fi eld had also been 
reported by cardiac surgeons using aprolinin , although 
dryness is an admilledly subjecti ve assessment and diffi-
cult to quanlify. The resulls of our initial report were 
confinned by the group of RoUes at the Royal Free Hos-
pital , London . England. 10-12 However, those workers 
applied aprotinin according 10 the dosage prolocol estab-
lished by Royston2 and associales with Ihe modification 
of adding 0.07 million KIU of aprotinin 10 each unit of 
blood Iransfused intraoperatively (Table I). In this relro-
speclive study with hislorical controls, the invesligators 
found . besides significant reductions in total transfusion 
requiremenls, especially in the poslanhepatic stage, and a 
shortening of the operative time in patienls receiving 
aprolinin , a significant reduction of the mean lenglh of the 
ICU stay and thus concluded that aprotinin treatment im-
plied overall reduction of the costs of liver transplantation. 
Because of Ihese initial experiences with aprotinin, 
our group fe it Ihat a properly randomized placebo-con-
trollcd trial would submit the patients in the control group 
to an unjustified risk , and we Iherefore continued to use 
aprotinin with careful prospeclive monitoring for even-
tual side effecls and concomitant analysis of parameters 
of the coagulation and fibrinolysis systems. Orthotopic 
liver transplantalion was carried out according to estab-
TABlE 1. Dosage Regimens for Aprotinin 
Application in Orthotopic liver Transplantation 
Dose Melhod of 
Reference (milliOlI KJU) Admi"istratio" 
BechSlein el al 
( 1991)>J 
0 .5 Inducl ion bolus 
0.5 
0.5 
Grasse CI al ( 199 1)17 2.0 
Groll el al {I 992)19 0.5/hour 
(Royslon el al 1981)1 
Mallcu el al (199 1)'2 2.0 
Himmel rich et a[ 
( 1992)18 
0.5lhour 
0.01 
O.21l1our 
O.4/hour 
O. I!hour 
Anhepalic bolus 
Reperfusion bolus 
Induction bolus 
Conlilluous infu sion 
Induclion bolus 
Continuous infusion 
Per unit of RBC 
Induction infus ion 
Anhepatic infusion 
Skin closure postop. day 3 
lished surgical techniques with routine use of a veno-
venous (portofemoral- axillary) bypass driven by a cen-
trifugal pump (Biomedicus, Minnetonka , MN) . 
Substitution of packed red blood cells (RBC) was aimed 
at maintaining a hemoglobin concenlration > 10 mg/dl . 
With each unit of RBC , one unit of fresh frozen plasma 
(FFP) was usually administered except in patients with 
severe ascites, who received additional units of FFP 10 
compensale for Iheir massive protein loss. Whole blood , 
fresh whole blood, or platelets were not given. The Cell 
Saver for autologous blood transfusion or a rapid infusion 
pump were never used. \3 
In 46 conseculive patients receiving primary Ijver 
graft s according to Ihis protocol, and with bolus adminis-
Iration of aprotinin (see above), the mean transfusion 
rcquircments were 7.5 ± 4.6 units of RBC and 
9. I ± 6.7 units of FFP. These reductions of homologous 
blood product requirements were not stalistically signifi-
cantly differenl from that of the initial historical control 
group (9 .7 ± 5.5 units of RBC and 10.4 ± 6.2 units of 
FFP). However, our expcrience compared very favorably 
with previous reports on blood product usage in OlT 
(Table 2) .8.14- 16 Furthennore , in 10 patients who re-
ceived aprotinin , detailed analyscs of the coagulalion and 
fibrinolysis system were carried out. 7 Aprotinin did not 
prevent Ihe increase of tissue plasminogen aclivalor (1-
PA) acti vity during the anhepalic phase, bUI the maximal 
values oft-PA aCli vily were lower than those reported by 
other investigators who did nol use aprot inin intraopera-
ti ve ly .~ Using thc aprolinin dosage recommended by 
Royston and associales2 (Table I) , Grossc el al17 Te-
poned a 50% reduction of mean homologous blood prad-
uct requiremcnts in a prospeclive study of25 consecutive 
pat ienls compared wilh 25 historica l controls. The I-PA 
aClivity levels werc significantly lower at thc time of 
repcrfusion of the graft than in the COn!rol group (see also 
the article by Grossc et al in this issue). 
Because other invesligators had not observed higher 
risk of thrombosis al vascular anaslomoses using high-
dose aprotinin as in cardiac surgery . we carried out a 
TABlE 2. Intraoperative Blood Product 
Requirements in Orthotopic liver Transplantation* 
U" i/s U" ilS 
Referl'"a of RBC ofFFP 
Bontcmpo CI al , Piusburgh ( 1985)8 42.8 39.9 
l.ewis CI a1. Piusburgh ( 1981)14 21.0 26.0 
Farrar cl aL SI. Louis (1988)u 22.0 38.2 
Chapin CI al , Omaha ( 1989)"'> 14.3 16.4 
Bechste in el al . Berl in ( 199 1)ll 7.6 9. 1 
(wilh aprotinin) 
• First OL T in adul ts, mean values. 
TABLE 3. Aprotinin Application (Million KIU) in 
Randomized Trial 
HO/IIS 
(11 "" 13) 
0 .5 
0' 
0.' 
Tilll<' 
Imluc!ion of ane s lhcs i~ 
Anhcpalic phase 
Reperfusion 
Skin cJ{)~urc (hC[x.rin 250 IU/h: 
heparin 500 IU/h slaning 12 h 
postup: poSIOp. day 3) 
".jusi"" 
(11 "" 10) 
O.2/hour 
OA/hour 
O. I/hour 
Because olher invesligalors had nOI observed higher 
risk of thrombosis at vascu lar anasl0n10SeS using high-
dose aprotinin as in cardiac surgery. we carried out a 
randomized conl rolled trial compari ng our aprOlinin bo-
lus regimen (n = 13; Group I) with a conrin uous intrave-
nous infus ion prolocot (n = 10: Group 2) (Tabte 3).'8 
Wirh conti nuous infusion, constanrly and significant ty 
higher syslemic aprotinin concentrat;ons could bc ob-
rained evcn during rhe preanhepatic phase and throughout 
rhe enri re procedure compared with bolus applicarion 
(Fig . I). There was a trend roward lower transfusion 
requ iremenrs in Group 2: however, it reached slaristicat 
significance fo r RBC usage only wirhi n Ihe fi rst 3 postop-
erative days (Table 4) . Ni ne of the patienrs in Group 2 
showed no signs of hyperfibrino lys is as defincd by read-
ings fro m the rhrombelastogram, and only one patient 
developcd severe hypcrfibri nolysi s . In comparison, 3 
TABLE 4, Blood Product Requirements (Median. 
Range) in Randomized Trial Comparing Aprotinin 
Bolus Treatment (Group 1) with Continuous 
Aprotinin Infusion (Group 2) 
Grollfl / C""'fI 2 
(1/ = IJ ) r" = /0 ) /I VII/I/<' 
RBC in!raop. 8 (4-26) 7 (2- 20) NS 
FFP in/Taop. tO.5 0 - 35) 8 12- 2l!) NS 
RBC postop . day 3 3.5 (0--9 ) 1.5 (0-6) < 0.05 
FFP POStOp. day 3 9 .5 (4-22) 6 .5 (0--171 NS 
and 4 of 13 patienrs from Group I showed mild hyper-
fibrinolys is and severe hyperfibrinolysis , respcclively 
(Table 5) . 
In contrast to these results. Ihe on ly placebo-con-
trolled. randomized srudy of aprorin in in liver tmnsplan-
larion wilh a dosing scheme according 10 Royston lmd 
associates, 2 carried out by the Munich group, cou ld nol 
confirm a beneficial effcci of aprolinin with regard to 
blood product requirernenrs or orher of rhe aforemen-
tioned criteria. I <) The aprot in in group necded 18 un its of 
RBC, whereas the control group necded 20 units (NS). 
The various aproti nin dosage schemes ernployed 
during OL T and publ ished 10 dare lire summarized above 
in Table I. More mcaningful may be a comparison or the 
10lal estimaled aprot inin dose used intraopcrat ivety by 
various in vesli gators togelher wilh the mean transfusion 
rcqui remenrs (Table 6) or the aprot inin plasma levels 
INTRA- / POSTOPERATIVE APROTININ LEVELS 
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KIU/ml 
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FIG. 1. Serum Aprotinin Concentra-
tions According to Method of Admin-
istration. Time 1 : after induction 01 
anesthesia; 2 : 5 minutes before an-
hepatic phase ; 3 .. 10 minutes after 
beginning of anhepatic phase; 4 = 5 
minutes before reperfusion; 5 "" 5 
minutes after reperfusion; 6 : 15 min· 
utes after reperfusion; 7 : 1 hour after 
reperfusion; 8 = 12 nours after reper -
fusion. 
TABlE 5. Incidence and Severity of Hypetfibrinolysis 
du ring Ol T with Bo lus vs Continuous Infusion 
Application of Aprotinin 
Se.wiry vf Bolus fnfilsion 
Hyptrjibrinofysis (Ir 0; lJ) (n 0; 10) 
None 6 9 
(W BLP > 120 min) 
Mild 3 0 
(WBLT· 'X}- 120) 
$cvere , 
(WBLT· < 90 min) 
., WBL T - whole blood elot lysis time as measured by thrombelastQ-
gram. 
transfusion requirements of 18 units of RBC. These dif-
ferences are difficult to explain other than by speculating 
that on the one hand . the rnet iculous blood component 
therapy employed by the Munich group, which varies 
from the practice of most other transplant centers,20 
counteracted potential effects of aprotinin, and that on 
the other hand, differences in the select ion and perioper-
alive management of the patients led to greater transfu-
sion requirements. 
POSSIBLE MECHANISMS OF ACTION 
OF APROTININ ON HEMOSTASIS 
DURING OLT 
Thorough investigations of hemostasis in our pa-
tients suggest thai aprotinin bolus Iherapy led to smaJler 
TABlE 6. Blood Product Requirements and Total 
Estimated Aprotinin Dose in Clinical Studies during 
Orthotopic Liver Transplantation 
MemrRBC TO/1I1 
Apro/inin 
Treatment Comrol Dost 
Referent'e Group Group (million K/U)* 
Sechsteln eI all) ( t99l)t 7.5 9.7 1.5 
Grosse et a l" (199 I)t 8. 1 23.3 5.0 
Malleu et al,2 ( 199 I)t 7.5 23.6 5.6 
Groh et al'~ (1992):1: 18.0 200 5.' 
Himmelreich et al' 8 (l 992)§ 7.0 8.' 2.0 
·Calculated assuming a 6·hour operation w;th substi tution of 8 units of 
RBC. 
t Historical oontrols. 
* Randomized placebo·controlled study. 
§ Randomized study of bolus vs COnlinuous infus ion of aprotinin (me· 
dian va lues). 
TABlE 7. Hemostatic Parameters in Petfusate 
(Median, Range) from Aprotinin Bo lus 
Treatment (Group 1) and Continuous Aprotinin 
Infusion (Group 2) 
Grmjp I Group 2 
(N 0; 13) (N = 101 P Valllc 
t·PA activily (tU) 12 (0.7- 23.6) 5 (0.7- 17.4) 0. 10 1 
t·PA antigen (ng/ml) 12.3 (7.2- 26.6) tO. 1 (1.2- 19.3) 0.050 
PAJ activity (AU) 6.4 (0-22) 17.8 (8.&-30.4) 0.043 
Cl 2·Antiptasmin (%) 63 (5-95) 9J (68-102) 0.010 
increases of profibrinolylic parameters than in the experi-
ence of other groupS.7 In a randomized controlled study 
of four patients in each group , comparing standard treat-
ment wilh aprolinin infusion according 10 the Royslon 
protocol, Couam el a12 1.22 showed that I-PA levels were 
significantly lower in the aproti nin-treated patients at the 
end of the anhepatic phase . a fi nding similar to that 
observed in Ihe slUdy of Grosse el al t7 (see above) . Fur-
Ihennore, Cotlam and assoc iates reponed significantly 
higher levels of Q.2-anliplasmin during all stages of li ver 
transplantation following admini stration of aprotinin . 
They therefore hypothesized that aprotinin reduces t-PA 
produclion by inh ibi ting katlikrein and that aprotinin's 
known antiplasmin effec i might neutralize plasmin 
fonned by t-PA or kallikrein.2t .22 
The antifibrinolytic effect of aprotinin has also been 
demonstrated in an in vitro study by treati ng blood sam-
pies oblained during OL T with aprotin in before perfonn-
ing IhromboeJastography. 23 
The graft itsclf may play an imporlant role in the 
developrnent of hyperfibrinolysis after reperfusion. This 
has heen evident clinically through the obscrvation that 
oozing becomes apparent exclusively after revascu lariza-
tion and has to be expected especia ll y when using grafts 
with scvere ischemic damage or primary nonfunction. 
Besides monitoring the systemic levels of coagulation 
and fi brinolysis faclOrs, we wondered whether the graft 
itself might release activators of fibrinolysis. Therefore, 
blood passing through the li ver immediately after reper-
fusion and collected by venting the inferior vena cava 
was collected and analyzed. t8.24 In the previously men-
tioned randomized cornparison of 13 patients receiving 
aprotinin bolus therapy with 10 patients receiving con-
tinuous aprotinin infusion, t-PA antigen and acti vity 
were lower. whereas PAT and Q.2-antiplasmin activities 
were higher in the perfusate collected from patients of 
the infusion group (Table 7). These resulls may be ex-
plained by the hypothesis Ihat higher aprot inin levels 
will reduce endothelial damage in the liver graft during 
reperfusion. 
EFFECTS OF APROTININ ON 
GRAFT PRESERVATION 
Lie cl al 25 first descri bed a proteclive effeci of apro-
tinin agaiost isehernic hepatocellular damage both in 
models ofwann hepa!ic isehern ia induccd by clamping of 
the hcpatoduodenal ligament in nonnal aod cirrhotic rats 
aod in cold isehern ia in a model of OlT in rats by pre-
trcating the livcr donors with aprotin iß. However. the 
results could not be confirmed in the isolated perfused rat 
li ver modcl. "u, On the olhcr hand, a large-animal study 
involving OLT in pigs dcmonstrated that treating the 
recipicms wilh a conlinuQus intravenous infusion of apro-
tinin resulted both in significantly less hepatocelJular 
isehernic damage , as renecled by postoperative serum 
levels of markers of liver cell integrity (SGOT), and 
significantly prolonged survival in comparison to eon-
trols. 27 These lauer swdies underseore a polential role of 
aprolinin in the prevenlion of repcrfusion injury ralher 
Ihan effecis during cold Siorage. as only Ihe liver reeipi-
enls were Irealed. 
ADVERSE EFFECTS OF APROTININ 
Because aprolin in is of bov ine origi n, anaphylacloid 
reaclions may be obscrved, as with any olher foreign 
prolein. espccially during repcated exposure afler poten-
lial antibody format ion. Although we have never encoun-
lered such reaclions in more Ihan 300 li ver transplan-
lations using aprolinin, not even after repeated 
administration (e.g . , in the setting of retransplantation of 
the liver), severe anaphylactoid reaelions have been re-
portcd . In a swdy involving more than 150 patients un-
dergoing cardiae surgery, one single ease of severe hy-
potension Ihoughtlo be attributable to aprotin in has been 
reported .4 Recently, such anaphylaet ic reae tions were 
shown 10 be IgF medialed. 28 lt Iherefore scems advi sable 
to obtain a medieal history of possible previous aprotinin 
exposure before treatment and to be prepared for appro-
priate management of any anaphylaeloid reaellons. 
Antihistamine reeeptor drugs can be adminisle red dur-
ing induetion of anesthesia and before aprolin in adm inis-
trdlion ; inlraoperative use of steroids is part of the proto-
eol in most Iransplant centers and would also counterael 
anaphylaetoid reaetions. 
CONClUSION 
A number of clinieal stud ies have now shown a 
reduelion of blood produel requirements and deereased 
tendenc ies for fibrinolysis , especialJ y during Ihe anhe-
patk and early reperfusion phase ofOLT, when aprotinin 
is administered intraopcrativcly. However, a large ran-
dom ized trial with suffieient numbers of patienls and , 
preferably, a multicenterdesign is st ililaeking 10 confiml 
the protective effecls of aprotinin and the optimal dose 
beyond any doubL 
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